ReviewInternational journal of breast cancer2025
Exploring the Potential of Mitochondria-Targeted Drug Delivery for Enhanced Breast Cancer Therapy.
Review in International journal of breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Strategies for Targeting Mitochondria in the Treatment of Breast Cancer.ACS pharmacology & translational science · 2026Review
- Mitochondrial Transplantation as a Therapeutic Strategy for Inherited Mitochondrial Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- The Multifaceted Role of Mitochondria in Angiogenesis.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer stands as the utmost prevalent malignancy in women, impacting the epithelial tissue of the breast and often displaying resistance to effective treatment due to its diverse molecular and histological features. Current treatment modalities may exhibit decreasing efficacy over time and can lead to disease progression. The mitochondria, a crucial organelle responsible for cellular metabolism and energy supply, stand highly sensitive to both heat and reactive oxygen species, presenting an assuring target for photodynamic and photothermal therapies (PTTs) in cancer cure. The employment of nanodrug carriers for combination deliveries holds promise in addressing challenges related to drug degradation and off-target toxicity. By circumventing the reticuloendothelial system, nanocarriers bolster the drug's bioavailability at the intended site and ensure controlled codelivery of multiple drugs, thereby maintaining the normal pharmacokinetic features and the regular pharmacodynamic characteristics of different therapeutic mechanisms. The precision and efficacy of this innovative technology have revolutionized drug delivery, substantially enhancing treatment effectiveness. In the pursuit of targeting mitochondrial modifications in cancer cells, various combination therapies such as photodynamic therapy (PDT), PTT, and chemodynamic therapy (CDT) have been explored. These therapies have improved the efficiency of mitochondria-targeted cancer treatment due to their advantageous properties of minimal toxicity, noninvasiveness, reduced drug resistance, and a safer profile. Our review article provides an exhaustive overview of alterations in the mitochondrial environment in BC, their impact on BC development, potential mitochondrial targets for BC treatment, nanotherapeutic approaches for targeting mitochondria, and the limitations of these approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.